Joern Aldag: We do know that a significant number of immunotherapies are sub-optimally working with regard to efficacy because they’re lacking T cells at the site of the tumor. For that reason, we were claiming that we’re able to drive on very high levels of antigen specific T cells. And that this ability to drive these antigen specific T cells towards the tumor could actually help a number of different immunotherapies to work. You may remember that last year at AACR, we demonstrated the combination with some 4-1BB. In this AACR presentation, you will be looking at a different immunotherapeutic IL-2, which we think has a significant promise in combination with HB-200 as well. And what we’re what we’re trying to show, albeit preclinical for the time being is that with these types of combinations, we can actually significantly enhance therapeutic effects in cancer patients across many different diseases.
And we’re very pleased that at AACR, we have the minisymposium going over a presentation of that data that you’re referring to.
Operator: And we’ll go next to Asthika Goonewardene at Truist Securities.
Asthika Goonewardene: I want to go back to the first question asked about the bar here in the patients with the data they’re looking forward during the second quarter. You told us about in response rate, but as we know I-O also shows that the denial works, you have a nice durable response of. What do you think is the boss of duration of response and in both those cohorts that you’re planning on presenting? And I’ve got a couple of follow-ups on that.
Joern Aldag: Katia.
Katia Schlienger: Yes. So, we’re planning on so to look at a number of other efficacy endpoints like disease control rates. Indeed, sometimes and we have shown that with our vector as a single agent. We see some patient with stable disease for months. And so, we’re planning to report that as well. In terms of duration of response, this will be what we will have knowing that we have started and wanting to patient at the beginning of 2022. So, we will put in the maximum of data that we have at this point we guided to 10 to 20 patients in first line and 10 to 20 patients second line.
Asthika Goonewardene: So maybe I’ll ask more directly. Do you think the duration of response data will be maturing enough to see a signal when you present this data in the second quarter? Or will you need more follow-up to really understand what the median duration of responses in these cohorts?
Katia Schlienger: Yes, we will probably need to continue to follow up here. It’s quite frequent that for this kind of data. There’s update something that are regularly at each of the conference. So, we will continue to follow-up the patient no matter what. This would be a first release that we will continue to follow up the patient and provide regular updates at scientific conference.
Joern Aldag: So, I think this is important to note. Yes, Sorry Katia.
Katia Schlienger: No, go ahead, Joern.
Joern Aldag: Yes, it’s important to note that the median progression free survival, for example, for pembro alone is very short. And while we will not have data that has fully matured across the entire data set of patients, you will be able to see how we compare against the median progression free survival from pembrolizumab.
Asthika Goonewardene: And when you’re looking at this at the more longer term follow-up that either hopefully later this year or maybe early next year, what is the bar then for progression free survival or duration of response that you would like to see, given that you said that you’re looking for double the ORR? Would you want to see double the median PFS or double the duration?
